Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 0.7% Following Insider Selling

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price traded down 0.7% on Monday after an insider sold shares in the company. The company traded as low as $6.03 and last traded at $6.07. 1,184,366 shares were traded during trading, a decline of 80% from the average session volume of 5,826,398 shares. The stock had previously closed at $6.11.

Specifically, CEO Christopher Gibson sold 20,000 shares of the stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $6.16, for a total value of $123,200.00. Following the sale, the chief executive officer now directly owns 762,656 shares of the company’s stock, valued at $4,697,960.96. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $6.22, for a total value of $71,200.34. Following the transaction, the director now directly owns 7,098,428 shares in the company, valued at $44,152,222.16. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on RXRX shares. Needham & Company LLC lowered their price target on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, September 4th. Leerink Partners lowered their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. Jefferies Financial Group lowered their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Finally, KeyCorp lowered their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Recursion Pharmaceuticals has an average rating of “Hold” and a consensus price target of $9.40.

Recursion Pharmaceuticals Trading Up 1.1 %

The business has a fifty day moving average of $6.83 and a 200-day moving average of $8.02. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of -3.79 and a beta of 0.80. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The company had revenue of $14.42 million during the quarter, compared to analyst estimates of $11.96 million. During the same quarter last year, the business earned ($0.38) EPS. The company’s revenue for the quarter was up 30.9% compared to the same quarter last year. On average, equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors have recently bought and sold shares of RXRX. Mubadala Investment Co PJSC acquired a new stake in Recursion Pharmaceuticals during the 4th quarter worth about $128,041,000. ARK Investment Management LLC boosted its position in Recursion Pharmaceuticals by 14.5% during the 2nd quarter. ARK Investment Management LLC now owns 28,142,918 shares of the company’s stock worth $211,072,000 after acquiring an additional 3,555,357 shares during the period. Baillie Gifford & Co. boosted its position in Recursion Pharmaceuticals by 10.5% during the 2nd quarter. Baillie Gifford & Co. now owns 26,589,936 shares of the company’s stock worth $199,425,000 after acquiring an additional 2,522,132 shares during the period. Kinnevik AB publ boosted its position in Recursion Pharmaceuticals by 14.4% during the 2nd quarter. Kinnevik AB publ now owns 11,905,668 shares of the company’s stock worth $89,293,000 after acquiring an additional 1,500,000 shares during the period. Finally, Lingotto Investment Management LLP lifted its holdings in shares of Recursion Pharmaceuticals by 69.0% during the 2nd quarter. Lingotto Investment Management LLP now owns 3,675,077 shares of the company’s stock valued at $27,563,000 after buying an additional 1,500,000 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.